Press Release

Astellas Announces Management Structure

TOKYO, February 8, 2022 - Astellas Pharma Inc. (TSE: 4503, President and CEO: Kenji Yasukawa, Ph.D., "Astellas") today announced the following Top Management members effective from March 1 and April 1, 2022.

Top Management

As of March 1, 2022, We will welcome a new Chief Financial Officer (CFO) from outside the company. As of April 1, 2022, the position of General Counsel (GC) and Chief Manufacturing Officer (CMfgO) as Top Management will be newly created, respectively. The position of Chief Business Officer (CBO) will be dissolved, and its role will be integrated into Chief Strategy Officer (CStO) .

■Appointment of new CFO

Minoru Kikuoka, who has held major positions in management and finance in various industries such as banking, chemicals, and electronics, and has a wealth of knowledge and experience in corporate management and governance, will join

Astellas as CFO on March 1.

■ Addition of GC to the Top Management

In addition to the role of GC as a "guardian" for protecting the company's interests from legal risk from a company-wideperspective, to proactively participate in VALUE creation in corporate management, GC will be appointed as a member of Top Management. Catherine Levitt, J.D., who has contributed to supporting the company globally in her current role as General Counsel and Executive Vice President, Legal., will continue her role as the General Counsel and Executive Vice President, Legal, and will be added to Top Management.

■ Addition of CMfgO to the Top Management

To strengthen and expand the capabilities of pharmaceutical technology for stable supply and commercialization of various modalities with the evolution of the Focus Area (FA) approach, we have decided to make CMfgO a member of Top Management. Hideki Shima, who has contributed to the establishment of CMC

(Chemistry, Manufacturing and Control) research and production structure that

supports a variety of modalities, will be appointed to the newly established position of CMfgO, and he will concurrently serve as President, Pharmaceutical Technology.

1

■Integration of CBO and CStO

The position of CBO will be dissolved, and its role will be integrated into CStO. We believe that having both roles for strategy and execution in CStO can accelerate our business toward achieving Corporate Strategic Plan 2021.

TOP Management

Title

Name

New

Representative Director,

Kenji Yasukawa

President and Chief Excecutive Officer (CEO)

Representative Director,

Naoki Okamura

Corporate Executive Vice President,

Chief Strategy Officer (CStO)

Chief Administrative Officer (CAO) and

Fumiaki Sakurai

Chief Ethics & Compliance Officer (CECO)

Chief Medical Officer (CMO)

Bernhardt Zeiher

Chief Commercial Officer (CCO)

Yukio Matsui

Chief Scientific Officer (CScO)

Yoshitsugu Shitaka

Chief Financial Officer (CFO)

Minoru Kikuoka

✔

General Counsel (GC)

Catherine Levitt

✔

Chief Manufacturing Officer (CMfgO)

Hideki Shima

✔

About Astellas

Astellas Pharma Inc. is a pharmaceutical company conducting business in more than 70 countries around the world. We are promoting the Focus Area Approach that is designed to identify opportunities for the continuous creation of new drugs to address diseases with high unmet medical needs by focusing on Biology and Modality. Furthermore, we are also looking beyond our foundational Rx focus to create Rx+® healthcare solutions that combine our expertise and knowledge with cutting-edge technology in different fields of external partners. Through these efforts, Astellas stands on the forefront of healthcare change to turn innovative science into value for patients. For more information, please visit our website at https://www.astellas.com/en.

Cautionary Notes

In this press release, statements made with respect to current plans, estimates, strategies and beliefs and other statements that are not historical facts are forward-looking statements about the future performance of Astellas. These statements are based on management's current assumptions and beliefs in light of the information currently available to it and involve known and unknown risks and uncertainties. A number of factors could cause actual results to differ materially from those discussed in the forward-looking statements. Such factors include, but are not limited to: (i) changes in general economic conditions and in laws and regulations, relating to pharmaceutical markets, (ii) currency exchange rate fluctuations, (iii) delays in new product launches, (iv) the inability of Astellas to market

2

existing and new products effectively, (v) the inability of Astellas to continue to effectively research and develop products accepted by customers in highly competitive markets, and (vi) infringements of Astellas' intellectual property rights by third parties.

Information about pharmaceutical products (including products currently in development) which is included in this press release is not intended to constitute an advertisement or medical advice.

###

Contacts for inquiries or additional information:

Astellas Pharma Inc.

Corporate Advocacy & Relations

TEL: +81-3-3244-3201

3

Attachments

  • Original Link
  • Original Document
  • Permalink

Disclaimer

Astellas Pharma Inc. published this content on 08 February 2022 and is solely responsible for the information contained therein. Distributed by Public, unedited and unaltered, on 08 February 2022 04:20:07 UTC.